PTH Analog Receptor Selectivity via Beta-Amino Acid Substitution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack the ability to rationally design receptor state-selective agonists for therapeutic applications, particularly for treating hypoparathyroidism, which are essential for minimizing side effects and effectively managing conditions like hypoparathyroidism.
Innovation Solution
Development of backbone-modified analogs of the peptide agonist PTH(1-34) by replacing selected α-amino acid residues with β-amino acid residues, creating unnatural peptide agonists with altered receptor-state selectivity patterns, thereby achieving distinct binding profiles and in vivo behaviors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional PTH analogs are used to treat hypoparathyroidism, then calcium levels can be maintained, but side effects occur due to lack of receptor state selectivity
Solution Approach 1:
The patent applies local quality by making specific positional substitutions of α-amino acid residues with β-amino acid residues at defined positions (e.g., positions 1, 5, 7, 14, 19, 20, 24, 28, 32) in the PTH(1-34) sequence. This localized modification strategy creates analogs with distinct binding profiles for R0 and RG receptor states, enabling selective activation of desired signaling pathways while minimizing activation of pathways that lead to side effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying the pattern, number, and position of β-amino acid substitutions to create a library of analogs with different receptor state selectivities. By changing these structural parameters, the patent achieves diverse binding profiles that can be optimized for specific therapeutic needs, balancing effectiveness with reduced side effects.
2Reliability
If current PTH treatments are administered, then hypoparathyroidism symptoms can be managed, but renal damage may occur due to non-selective receptor activation
Solution Approach 1:
The patent uses local quality by implementing targeted β-amino acid substitutions at specific positions within the PTH sequence. These localized structural changes create analogs that selectively activate the R0 or RG functional states of the PTH receptor, thereby managing hypoparathyroidism while avoiding non-selective activation that leads to renal damage.
3Measurement precision
If rational design methods are developed for receptor state-selective agonists, then therapeutic precision can be improved, but design complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the PTH(1-34) sequence into specific positional segments where β-amino acid substitutions can be independently varied. This segmentation approach allows systematic exploration of structure-activity relationships at different positions, creating a rational design framework that manages complexity through modular, position-specific modification strategies.
Solution Approach 2:
The patent uses parameter changes by establishing a systematic framework for varying substitution patterns at defined positions. This creates a rational design methodology where the complex problem of receptor state selectivity is broken down into controllable parameters (position, type, and pattern of substitutions), enabling precise control over analog properties.
Data Source
AI summary
Described are polypeptide analogs of parathyroid hormone (PTH) that include at least two non-adjacent β-amino acid residues in place of a naturally occurring α-amino acid residues. Also described are pharmaceutical compositions useful for treating hypoparathyroidism that contain the analogs and methods of using the analogs to treat hypoparathyroidism.